Xtent axes 93% of staff to preserve cash
This article was originally published in Clinica
Executive Summary
In a move to conserve its finances, drug-eluting stent specialist Xtent is set to cut 112 employees by March 23 2009. These cuts would represent a 93% reduction in its total employment base of 121 members of staff. The Menlo Park, California-based company is also enlisting the help of an unnamed investment bank in order to identify strategic alternatives, which may include the sale of some of its assets, or a merger or acquisition deal. The firm’s president and CEO, Gregory Casciaro, said that Xtent was reducing its activities to “a critical minimum” in a bid to boost shareholder value – the company’s shares having been trading at under $1.00 since November 2008. Last year, Xtent cut 73 of its staff in order to minimise expenses (see Clinica No 1315, p 14).
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals